Disciform Scar (End-Stage Wet AMD): Signs and Outlook

Disciform scar is the fibrovascular end stage of neovascular age-related macular degeneration (AMD).

It replaces the central photoreceptors and retinal pigment epithelium (RPE) with fibrous tissue.

As a result, central acuity rarely recovers, although peripheral vision usually persists.

---

What a Disciform Scar Is

Macular neovascularization leaks fluid and blood beneath the RPE or the neurosensory retina.

Then fibroblasts, glial cells and RPE cells organize this exudate into a fibrous plate.

Histopathology also shows that new vessels can persist within the fibrous tissue.

Why Scars Form Despite Treatment

Anti-VEGF therapy dries many lesions, but it does not reliably prevent fibrosis.

For example, the CATT analysis linked scarring to baseline features, including classic neovascularization.

Symptoms of Disciform Scar

Patients typically describe a fixed central blank patch and trouble reading or recognizing faces.

However, navigation usually remains possible because peripheral retina survives.

A sudden new decline suggests fresh hemorrhage and needs prompt examination.

Fundus Signs of a Disciform Scar

The examiner sees a white to yellow-gray subretinal mound centered on the macula.

Pigment clumps often outline the lesion, while surrounding atrophy marks older damage.

Next, inspect the margin for hard exudate, blood and serous elevation.

These findings suggest ongoing activity.

OCT Appearance of Disciform Scar

OCT shows a dense hyperreflective band or mound beneath the retina, the RPE, or both.

The overlying outer retina appears thin, and the ellipsoid zone is usually absent.

Outer retinal tubulation may appear as round spaces with hyperreflective borders.

Also, degenerative intraretinal cysts can mimic active edema, although they often fail to respond to injections.

Angiography and Autofluorescence

Fluorescein angiography typically shows late staining of the fibrous tissue without expanding leakage.

Autofluorescence often shows dark areas where the RPE has died.

Meanwhile, OCT angiography may reveal a persistent vascular network inside the scar.

However, flow alone does not prove activity, so correlate it with exudation and symptoms.

Active or Inactive Disciform Scar?

This question guides management more than the size of the lesion does.

Favor activity when you find new blood, growing subretinal fluid or exudate at the edge.

In contrast, stable OCT scans and unchanged vision favor inactive disease.

Differential Diagnosis

Several conditions can leave a similar macular scar, so age and history help.

Consider myopic neovascularization, inflammatory chorioretinal scars, choroidal rupture and advanced vitelliform lesions.

In addition, a thick pigmented or hemorrhagic lesion can resemble choroidal melanoma.

Ultrasound and serial imaging help when the appearance remains uncertain.

Does Anti-VEGF Help a Disciform Scar?

Injections target vascular leakage, but they cannot restore photoreceptors or remove fibrosis.

Therefore, a dry, stable scar generally offers little reason for continued treatment.

Treatment becomes reasonable when fresh blood or fluid threatens remaining function, including eccentric fixation.

Explain the limited goal clearly, because patients may expect injections to restore reading vision.

Also discuss endophthalmitis and other injection risks before each decision.

Surgery and Implantable Telescopes

Surgical removal of a mature scar seldom restores central vision because the overlying retina has already degenerated.

An implantable miniature telescope offers another option for selected patients with bilateral end-stage disease.

Its registration study reported improved acuity in many eyes, but also endothelial cell loss.

Because availability varies, candidates need careful selection and extended rehabilitation.

Prognosis After Disciform Scar

Vision usually stabilizes once the lesion becomes quiescent, although the central scotoma remains.

However, scars can enlarge, and atrophy can spread around them.

Total blindness from AMD alone is unusual because peripheral retina persists.

Low Vision Counseling

Begin referral early, while the patient still has motivation and useful function.

Next, a low vision rehabilitation program can teach eccentric viewing and fit magnifiers.

Lighting, contrast and electronic reading tools also help with daily tasks.

Finally, review driving rules, falls risk and local disability services.

Protecting the Fellow Eye

The second eye now carries most of the patient’s functional vision.

Therefore, teach daily monocular testing with an Amsler grid or a similar home tool.

Review smoking, AREDS2 eligibility and urgent reporting of new distortion.

Reviewing the differences between wet and dry AMD also helps patients recognize warning symptoms.

Follow-Up of Disciform Scar

Set intervals according to fellow eye risk and any signs of activity.

At each visit, record acuity, fixation behavior and functional complaints.

In addition, obtain OCT of both eyes and compare it directly with earlier scans.

Pitfalls to Avoid

• Do not treat degenerative cysts as active fluid without comparing serial scans
• An old scar is not always inactive, especially after new symptoms
• Melanoma can hide behind a thick or atypical lesion
• Low vision referral should not wait until injections stop
• The fellow eye needs attention even when the first eye seems finished

---

References

1. Green WR, Enger C. Age-related macular degeneration histopathologic studies. Ophthalmology. 1993;100:1519-1535.
2. Daniel E, Toth CA, Grunwald JE, et al. Risk of scar in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2014;121:656-666.
3. Zweifel SA, Engelbert M, Laud K, et al. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596-1602.
4. Hudson HL, Lane SS, Heier JS, et al. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology. 2006;113:1987-2001.